Wall Street brokerages expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to announce earnings per share (EPS) of ($0.24) for the current quarter, Zacks reports. Three analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.13). Dicerna Pharmaceuticals reported earnings of ($0.92) per share during the same quarter last year, which indicates a positive year over year growth rate of 73.9%. The firm is scheduled to report its next earnings report on Thursday, November 1st.

Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%.

Several equities research analysts have recently commented on the stock. B. Riley boosted their target price on shares of Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the stock a “neutral” rating in a research report on Monday, September 17th. Cowen reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Wednesday, September 5th. BidaskClub raised shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 23rd. Citigroup assumed coverage on shares of Dicerna Pharmaceuticals in a research report on Thursday, September 13th. They set a “buy” rating and a $27.00 target price for the company. Finally, HC Wainwright raised shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Wednesday, August 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. Dicerna Pharmaceuticals currently has an average rating of “Hold” and an average price target of $17.41.

In other Dicerna Pharmaceuticals news, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total value of $232,496.00. Following the completion of the sale, the director now directly owns 29,064 shares of the company’s stock, valued at approximately $465,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James B. Weissman sold 2,301 shares of the company’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.50, for a total transaction of $40,267.50. Following the completion of the sale, the insider now directly owns 26,781 shares of the company’s stock, valued at $468,667.50. The disclosure for this sale can be found here. Insiders own 19.85% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $102,000. Jane Street Group LLC bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $136,000. Verition Fund Management LLC bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $141,000. State Board of Administration of Florida Retirement System bought a new stake in Dicerna Pharmaceuticals in the 2nd quarter worth about $178,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in Dicerna Pharmaceuticals in the 2nd quarter worth about $188,000. 74.47% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:DRNA traded up $0.57 during midday trading on Monday, hitting $12.33. 1,006,100 shares of the company’s stock were exchanged, compared to its average volume of 555,737. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 5.40. The company has a market cap of $726.85 million, a PE ratio of -3.37 and a beta of 2.43. Dicerna Pharmaceuticals has a 12 month low of $4.91 and a 12 month high of $17.98.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Read More: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.